These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 30878206)
21. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Lindor KD; Jorgensen RA; Anderson ML; Gores GJ; Hofmann AF; LaRusso NF Am J Gastroenterol; 1996 Mar; 91(3):511-5. PubMed ID: 8633500 [TBL] [Abstract][Full Text] [Related]
22. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Okolicsanyi L; Groppo M; Floreani A; Morselli-Labate AM; Rusticali AG; Battocchia A; Colombo M; Galatola G; Gasbarrini G; Podda M; Ricci G; Rosina F; Zuin M Dig Liver Dis; 2003 May; 35(5):325-31. PubMed ID: 12846404 [TBL] [Abstract][Full Text] [Related]
23. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. Stiehl A; Walker S; Stiehl L; Rudolph G; Hofmann WJ; Theilmann L J Hepatol; 1994 Jan; 20(1):57-64. PubMed ID: 8201224 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study. Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678 [No Abstract] [Full Text] [Related]
25. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Harnois DM; Angulo P; Jorgensen RA; Larusso NF; Lindor KD Am J Gastroenterol; 2001 May; 96(5):1558-62. PubMed ID: 11374699 [TBL] [Abstract][Full Text] [Related]
33. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis. Stiehl A Scand J Gastroenterol Suppl; 1994; 204():59-61. PubMed ID: 7824879 [TBL] [Abstract][Full Text] [Related]
34. Bile acids for primary sclerosing cholangitis. Chen W; Gluud C Cochrane Database Syst Rev; 2003; (2):CD003626. PubMed ID: 12804480 [TBL] [Abstract][Full Text] [Related]
35. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168 [TBL] [Abstract][Full Text] [Related]
36. Effectiveness of Ursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis with Ulcerative Colitis: A Pediatric Case. Fujita Y; Sugaya T; Inui A; Yoshihara S Tohoku J Exp Med; 2021 Feb; 253(2):109-112. PubMed ID: 33551380 [TBL] [Abstract][Full Text] [Related]
37. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Smith T; Befeler AS Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyltranspeptidase levels. Kiso S; Kawata S; Imai Y; Tamura S; Inui Y; Ito N; Matsuzawa Y J Gastroenterol; 1996 Feb; 31(1):75-80. PubMed ID: 8808432 [TBL] [Abstract][Full Text] [Related]
39. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. Rolandi E; Franceschini R; Cataldi A; Cicchetti V; Carati L; Barreca T Eur J Clin Pharmacol; 1991; 40(5):473-6. PubMed ID: 1679391 [TBL] [Abstract][Full Text] [Related]
40. A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients. Sato S; Miyake T; Tobita H; Oshima N; Ishine J; Hanaoka T; Amano Y; Kinoshita Y World J Gastroenterol; 2009 Jun; 15(22):2782-6. PubMed ID: 19522030 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]